Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

N4 Pharma Plc (N4P) Share Price

Price 0.475p on 27-03-2025 at 17:30:01
Change 0.00p 0%
Buy 0.50p
Sell 0.45p
Buy / Sell N4P Shares
Last Trade: Buy 800.00 at 0.50p
Day's Volume: 7,574
Last Close: 0.475p
Open: 0.475p
ISIN: GB00BYW8QM32
Day's Range 0.475p - 0.475p
52wk Range: 0.412p - 0.925p
Market Capitalisation: £2m
VWAP: 0.471785p
Shares in Issue: 395m

N4 Pharma Plc (N4P) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 800 0.50p Ordinary
15:29:34 - 27-Mar-25
Sell* 1,374 0.45p Ordinary
12:42:35 - 27-Mar-25
Unknown* 5,000 0.475p Ordinary
12:09:58 - 27-Mar-25
Sell* 400 0.45p SI Trade
08:19:29 - 27-Mar-25
Buy* 400 0.50p SI Trade
11:17:14 - 26-Mar-25
Sell* 1,400 0.45p SI Trade
11:17:14 - 26-Mar-25
Buy* 2,262 0.50p SI Trade
11:14:20 - 25-Mar-25
Sell* 8,182 0.45p SI Trade
11:14:20 - 25-Mar-25
Buy* 2,400 0.50p SI Trade
11:14:20 - 25-Mar-25
Buy* 13,510 0.50p SI Trade
11:14:20 - 25-Mar-25
See more N4 Pharma Plc trades

N4 Pharma Plc (N4P) Share Price History

Time period:
to
Date Open High Low Close Volume
27th Mar 2025 (Thu) 0.475 0.475 0.475 0.475 7,574
26th Mar 2025 (Wed) 0.475 0.475 0.475 0.475 1,800
25th Mar 2025 (Tue) 0.475 0.475 0.475 0.475 28,554
24th Mar 2025 (Mon) 0.475 0.475 0.475 0.475 411,788
21st Mar 2025 (Fri) 0.475 0.475 0.475 0.475 3,400
20th Mar 2025 (Thu) 0.475 0.46 0.46 0.46 1,969,631
19th Mar 2025 (Wed) 0.475 0.50 0.475 0.475 1,489,590
18th Mar 2025 (Tue) 0.475 0.475 0.475 0.475 736,669
17th Mar 2025 (Mon) 0.475 0.475 0.475 0.475 274,358
14th Mar 2025 (Fri) 0.475 0.475 0.475 0.475 1,048,058
13th Mar 2025 (Thu) 0.475 0.475 0.475 0.475 693,785
12th Mar 2025 (Wed) 0.475 0.475 0.475 0.475 301,011
11th Mar 2025 (Tue) 0.50 0.50 0.475 0.475 3,714,591
10th Mar 2025 (Mon) 0.475 0.50 0.475 0.50 3,900,387
7th Mar 2025 (Fri) 0.525 0.50 0.50 0.50 1,565,697
6th Mar 2025 (Thu) 0.525 0.525 0.525 0.525 2,734
5th Mar 2025 (Wed) 0.525 0.525 0.525 0.525 44,750
4th Mar 2025 (Tue) 0.525 0.525 0.525 0.525 244,530
3rd Mar 2025 (Mon) 0.525 0.525 0.525 0.525 116,186
28th Feb 2025 (Fri) 0.525 0.525 0.525 0.525 255,000
See more N4 Pharma Plc price history

N4 Pharma Plc (N4P) Regulatory News

Date Source Headline
18th Feb 2025 12:34 pm RNS Holding(s) in Company
7th Feb 2025 7:00 am RNS-R Investor Webinar
27th Jan 2025 7:00 am RNS-R Investor Webinar
16th Jan 2025 7:00 am RNS-R N4 Pharma Non-Executive Director Q&A
8th Jan 2025 7:00 am RNS Directorate Changes
12th Dec 2024 7:00 am RNS N4 101 In Vitro Results
4th Dec 2024 7:00 am RNS New Patent Filing
28th Nov 2024 7:00 am RNS Grant of Options
24th Sep 2024 7:00 am RNS Interim Results
17th Sep 2024 8:04 am RNS SRI Research Update
See more N4 Pharma Plc regulatory news

N4 Pharma Plc (N4P) Share News

AIM WINNERS & LOSERS: Velocity Composites expects to beat market view

12th Dec 2024 10:40

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Thursday. Read More

AIM WINNERS & LOSERS: Biome warns on revenue; legal blow for LCM

4th Dec 2024 10:57

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Wednesday. Read More

EARNINGS: Metals One advances Black Schist, N4 generates revenue

24th Sep 2024 15:01

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More

IN BRIEF: N4 Pharma celebrates chemistry work update on Nuvec

20th Aug 2024 11:52

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company focused on the development of nanoparticle technology Nuvec - Notes SRI International has successfully completed the chemistry work and shown that a fox three molecular guidance system can be added to Nuvec without altering its loading capability. Chief Executive Nigel Theobald says: "This is an exciting development for us as it clearly shows that Nuvec is capable of targeting specific cells via the addition of a relevant ligand, something the industry is actively looking for. We will now start working on a combined marketing pitch deck allowing SRI and N4 Pharma to present this data and its implications to major pharma and biotech players that need a targeting delivery system for their nucleic acid programs." N4 Pharma says the next step is to show that small interfering RNA still retains its functionality in the target cell. Read More

AIM WINNERS & LOSERS: Shuka Minerals down on CLN drawdown

20th Aug 2024 10:24

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Tuesday. Read More

See more N4 Pharma Plc news
FTSE 100 Latest
Value8,666.12
Change-23.47

Login to your account

Forgot Password?

Not Registered